Hans Tillmann

12PUBLICATIONS
17CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsComputational logic and formal languagesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 22, 2026
Letter: Using Anti-HBs Titers to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours-Authors' Reply.

Hans L Tillmann, Shiva Poola, MaryKate Kratzer

|Dec 04, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Anna Fettiplace, Arie Regev, Alexandre Kiazand

|Sep 19, 2025
Finite Treatments for Viral Hepatitis : Is "Sustained Control" Versus Cure Acceptable for HBV?

Hans L Tillmann

|Sep 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.

Anna Fettiplace, John Marcinak, Michael Merz

|Oct 27, 2023
Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy.

Shiva Poola, MaryKate Kratzer, Kerry Sewell

|Sep 29, 2022
A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).

Hans L Tillmann, Ayako Suzuki, Michael Merz

Pageof 2

Frequent Collaborators

2 joint publications

Don Rockey

2 joint publications

Anna Fettiplace

2 joint publications

Arie Regev

2 joint publications

Adrian M Di Bisceglie